-
1.发明申请公开(公告)号：US20180271921A1
公开(公告)日：2018-09-27
申请号：US15758689
申请日：2016-09-02
申请人： SillaJen, Inc.
发明人： Tae Ho HWANG , Nam Hee LEE , Euna CHO
IPC分类号： A61K35/768 , C12N9/18 , C07K14/565 , A61K38/46 , A61K38/21 , A61K45/06 , A61P35/00
CPC分类号： A61K35/768 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K38/215 , A61K38/465 , A61K45/06 , A61K48/005 , A61P35/00 , C07K14/52 , C07K14/565 , C12N9/18 , C12N2710/24132 , C12N2710/24134 , C12N2710/24141 , C12N2710/24143 , C12Y301/01001 , A61K2300/00
摘要： The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer.
-
公开(公告)号：US20180303886A1
公开(公告)日：2018-10-25
申请号：US15738034
申请日：2016-06-17
申请人： SillaJen, Inc.
发明人： Tae Ho HWANG , Nam Hee LEE , Mong CHO , Ungbae JEON , Doo Jin BYUN
IPC分类号： A61K35/768 , A61K9/00 , A61K47/42 , A61P35/00 , C12N7/00
摘要： The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.
-
公开(公告)号：US20200085891A1
公开(公告)日：2020-03-19
申请号：US16606681
申请日：2018-04-23
申请人： SillaJen, Inc.
发明人： Chan KIM , Hongjae JEON , Eun Sang MOON , Sungkuon CHI , Jiwon Sarah CHOI , Joon-goo JUNG , Jungu BAE
IPC分类号： A61K35/768 , C12N7/00 , A61K38/19 , A61K9/00 , A61K39/395 , A61P35/00 , A61K45/06
摘要： A pharmaceutical combination comprising (i) a replicative oncolytic vaccinia virus and (ii) an immune checkpoint protein inhibitor is provided as well as a kit comprising the pharmaceutical combination and methods for treating and/or preventing cancer.
-
公开(公告)号：US20220381769A1
公开(公告)日：2022-12-01
申请号：US17761932
申请日：2020-09-23
发明人： Nicholas GASPAR , Raquel DEERING , Myles DILLON
IPC分类号： G01N33/50 , C07K14/005
摘要： Provided herein are methods and compositions for assaying vaccinia virus-specific T cell responses in a sample from a subject undergoing treatment with an oncolytic vaccinia virus. The compositions comprise custom peptide pools from known immunogenic vaccinia virus epitopes in an HLA-agnostic format to profile peripheral CD8+T cell responses.
-
公开(公告)号：US10517910B2
公开(公告)日：2019-12-31
申请号：US15738034
申请日：2016-06-17
申请人： SillaJen, Inc.
发明人： Tae Ho Hwang , Nam Hee Lee , Mong Cho , Ungbae Jeon , Doo Jin Byun
IPC分类号： A61K35/768 , C12N7/00 , A61K9/00 , A61K47/42 , A61K38/19 , A61K35/763 , A61P35/00
摘要： The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.
-
公开(公告)号：US20240067936A1
公开(公告)日：2024-02-29
申请号：US18278879
申请日：2022-02-25
申请人： SILLAJEN, INC.
发明人： Keunhee OH , Namhee LEE , Byung Jin JUNG , Jun Seung LEE , Kyeong Tae KANG
IPC分类号： C12N7/00 , A61K35/768 , A61P35/00 , C07K14/07 , C07K14/535 , C07K14/705 , C12N9/12 , C12N15/62
CPC分类号： C12N7/00 , A61K35/768 , A61P35/00 , C07K14/07 , C07K14/535 , C07K14/70596 , C12N9/1211 , C12N15/62
摘要： The present invention relates to an oncolytic virus and the use thereof, specifically, an oncolytic virus having suppressed thymidine kinase (TK) gene expression and comprising genes encoding granulocyte-macrophage colony-stimulating factor (GM-CSF) and a complement regulatory protein; and the use of such an oncolytic virus. The oncolytic virus of the present invention maintains its efficacy even when administered intravenously, and thus, it may also be applied to the treatment of various solid cancers and metastatic cancers in addition to superficial solid cancers. In addition, the oncolytic virus of the present invention acquires resistance to complement attack by expressing a complement regulatory protein on the surface of the virus, and thus, it is stable in the blood, and it maintains stable oncolytic activity when intravenous injection, and thus, it may reduce effective viral dosage to minimize the side effects of anti-cancer drugs.
-
公开(公告)号：US10646524B2
公开(公告)日：2020-05-12
申请号：US15758689
申请日：2016-09-02
申请人： SillaJen, Inc.
发明人： Tae Ho Hwang , Nam Hee Lee , Euna Cho
IPC分类号： A61K35/768 , C07K14/565 , C12N9/18 , A61K31/7068 , C07K14/52 , A61K31/513 , A61K31/519 , A61K31/337 , A61K31/4745 , A61K31/282 , A61K35/00 , A61K38/21 , A61K48/00 , A61P35/00
摘要： The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer.
-
公开(公告)号：US10434169B2
公开(公告)日：2019-10-08
申请号：US15892247
申请日：2018-02-08
发明人： David Kirn , John Bell , Caroline Breitbach , Anne Moon , Tae-Ho Hwang , Yu Kyoung Lee , Mi-kyung Kim
IPC分类号： A61K39/285 , A61K39/00 , C07K16/30 , A61K35/76 , A61K35/761 , A61K35/763 , A61K35/768 , A61K35/26 , A61K39/12 , A61K39/125 , A61K39/145 , A61K39/165 , A61K39/17 , A61K39/205 , A61K39/235 , A61K39/245 , A61K39/395 , A61K45/06 , C07K16/18 , C12N7/00 , G01N33/574
摘要： The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
-
公开(公告)号：US20180214538A1
公开(公告)日：2018-08-02
申请号：US15892247
申请日：2018-02-08
发明人： David KIRN , John BELL , Caroline BREITBACH , Anne MOON , Tae-Ho HWANG , Yu Kyoung LEE , Mi-kyung KIM
IPC分类号： A61K39/285 , A61K35/26
CPC分类号： A61K39/285 , A61K35/26 , A61K35/76 , A61K35/761 , A61K35/763 , A61K35/768 , A61K39/0011 , A61K39/12 , A61K39/125 , A61K39/145 , A61K39/165 , A61K39/17 , A61K39/205 , A61K39/235 , A61K39/245 , A61K39/395 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/55522 , C07K16/18 , C07K16/30 , C07K2317/14 , C07K2317/734 , C12N7/00 , C12N2710/10034 , C12N2710/16632 , C12N2710/16634 , C12N2710/24034 , C12N2710/24132 , C12N2720/12232 , C12N2750/14034 , C12N2760/16034 , C12N2760/18134 , C12N2760/18434 , C12N2760/18734 , C12N2760/20034 , C12N2760/20232 , C12N2770/32034 , C12N2770/32334 , C12N2770/36034 , G01N33/574
摘要： The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.034 秒)
